Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma

Wudhikarn, Kitsada; Bunworasate, Udomsak; Julamanee, Jakrawadee; Lekhakula, Arnuparp; Ekwattanakit, Supachai; Khuhapinant, Archrob; Niparuck, Pimjai; Chuncharunee, Suporn; Numbenjapon, Tontanai; Prayongratana, Kannadit; Kanitsap, Nonglak; Wongkhantee, Somchai; Makruasri, Nisa; Wong, Peerapon; Norasetthada, Lalita; Nawarawong, Weerasak; Chansung, Kanchana; Suwanban, Tawatchai; Praditsuktavorn, Pannee; Intragumtornchai, Tanin

doi:10.1002/hon.2687

Cited by 12 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Maurer et al [ 12 ] reported that patients with PTCL who remain event-free at 24 months have longer subsequent OS, even if it is shorter than the survival rate of the general population. Similarly, Wudhikarn et al [ 13 ] showed that EFS24 is an independent predictor of OS for PTCL.…”

Section: Discussionmentioning

confidence: 93%

See 1 more Smart Citation

Predictive Factors of Event-Free Survival at 24 Months in Patients with Peripheral T-Cell Lymphoma: A Retrospective Study

Kim

Lee

et al. 2022

Cancer Res Treat

View full text Add to dashboard Cite

Event-free survival at 24 months (EFS24) is known to be a surrogate marker for overall survival (OS) for patients with peripheral T-cell lymphoma (PTCL). We examined the role of EFS24 in PTCL compared to diffuse large B-cell lymphoma (DLBCL), and then assessed the clinical predictive factors of achieving EFS24. Materials and MethodsPatients with newly diagnosed PTCL treated with anthracycline-based chemotherapy were included. Subsequent OS was defined as the time elapsed from 24 months after diagnosis until death from any cause in those who achieved EFS24. ResultsOverall, 153 patients were evaluated, and 51 (33.3%) patients achieved EFS24. Patients who achieved EFS24 showed superior OS compared to patients who did not (p<0.0001). EFS24 could stratify the subsequent OS although it did not reach to that of the general population.After matching the PTCL group to the DLBCL group based on the international prognostic index, the subsequent OS in patients who achieved EFS24 was similar between the two groups (p=0.09). Advanced stage was a significant factor to predict the failing EFS24 by multivariable analysis (p<0.001). ConclusionPatients with PTCL who achieve EFS24 could have a favorable subsequent OS. Since advanced disease stage is a predictor of EFS24 failure, future efforts should focus on developing novel therapeutic strategies for PTCL patients presenting with advanced disease.

show abstract

Section: Discussionmentioning

confidence: 93%

“…Recent data showed that EFS24 achievement could predict favorable subsequent outcomes in PTCL patients [ 12 , 13 ]. There is no study for predictors of achieving EFS24 in PTCL.…”

Section: Introductionmentioning

confidence: 99%

Predictive Factors of Event-Free Survival at 24 Months in Patients with Peripheral T-Cell Lymphoma: A Retrospective Study

Kim

Lee

et al. 2022

Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…In the neoadjuvant setting, or for hematologic malignancies or other settings where interventions such as drugs, biologics, radiation therapy, or surgery would be used to render a patient free of detectable disease after a well-defined induction/neo-adjuvant period, a logical extension of the validated concept of DFS would be a time-to-event endpoint, with failure defined to be the earliest of the occurrence of: (a) failure to achieve disease-free status locally at the end of the induction and surgery period; (b) detection of recurrence of disease (either local post induction or distal) by CT; or (c) death. 6,[11][12][13] Figure 1 provides a graphical summary of this definition of EFS. This composite endpoint, which is a novel formulation of DFS applied in the neoadjuvant setting, seems particularly well suited to be a key measure of efficacy for therapeutic strategies in settings such as LAPC that may involve neoadjuvant treatment followed by surgery, with the goal of rendering such patients disease-free (locally and systemically).…”

Section: Formulating a Novel Event-free Survival Endpoint For Lapcmentioning

confidence: 99%

Section: Formulating a Novel Event-free Survival Endpoint For Lapcmentioning

confidence: 99%

A novel event-free survival endpoint in locally advanced pancreatic cancer

et al. 2021

View full text Add to dashboard Cite

The treatment paradigm for locally advanced pancreatic cancer (LAPC) is evolving rapidly. The development of neoadjuvant therapies composed of combination therapies and the evaluation of their impact on conversion to borderline resectable (BR) status, resection, and ultimately overall survival (OS) are presently being pursued. These efforts justify re-visiting study endpoints in order to better predict therapeutic effects on OS, by capturing not only the achievement of R0 resection at the end of induction therapy but also the long-term reductions in the rate of local and distal recurrence. The proposed herein event-free survival (EFS) endpoint, with its novel definition specific to LAPC, is formulated to achieve these objectives. It is an analog to disease-free survival (DFS) endpoint in the adjuvant setting applied to the neoadjuvant setting and may be a valuable surrogate endpoint for this patient population.

show abstract

“…In Asia, the prevalence of the three most common T-cell lymphomas is quite different, with a nearly equal distribution of PTCL-NOS, NK/T-cell lymphomas, and adult T-cell leukemia / lymphoma (ATLL). The latter two are up to twenty-five times more frequent in Asia than in North America or Europe [15][16][17][18].…”

Section: Introductionmentioning

confidence: 97%

Correlation between the prevalence of T-cell lymphomas and alcohol consumption

Desmirean

Richlitzki

Pașca

et al. 2021

Medicine and Pharmacy Reports

View full text Add to dashboard Cite

Background and aims. Alcohol is a psychoactive substance that causes dependence, with many thousands of years in the history of mankind, being widely used in different cultures. According to the International Agency for Research on Cancer, alcohol is involved in the development of cancer, being directly associated with it. Considering that alcohol is involved in the initiation and dissemination of gastrointestinal malignancies, the objective of the study was to assess its role in the pathogenesis of T-cell lymphomas, as well as its possible correlation with chronic consumption. Methods. The patient cohort was compiled from the Sixth Medical Center of the People’s Liberation Army Navy General Hospital in Beijing, China. A total of 30 patients matched the criteria and were enrolled in the study. Statistical analysis of the raw data was performed using R Statistics version R 3.5.1. released on the 29.08.2018. Results. Our data demonstrate that the most common extranodal involvment of T-cell lymphoma patients is represented in decreasing order by bone marrow, peritoneum, rhino-oropharynx and the liver-biliary system. Nodal involvement is mainly represented in decreasing order by the laterocervical, axillary, mediastinal and inguinal regions. Conclusions. These findings may be of value in further research and practical/clinical settings. Fever is the most common clinical feature and was present in most studied patients.

show abstract

Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma

Cited by 12 publications

References 29 publications

Predictive Factors of Event-Free Survival at 24 Months in Patients with Peripheral T-Cell Lymphoma: A Retrospective Study

Predictive Factors of Event-Free Survival at 24 Months in Patients with Peripheral T-Cell Lymphoma: A Retrospective Study

A novel event-free survival endpoint in locally advanced pancreatic cancer

Correlation between the prevalence of T-cell lymphomas and alcohol consumption

Contact Info

Product

Resources

About